32 Lymphoma Clinical Trials in Rochester, MI (2026)

Q: How do I join a clinical trial in Rochester?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you.

Recruiting Lymphoma Studies in Rochester

NCT00626496Recruiting

Family Study of Lymphoproliferative Disorders

Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolle...

Rochester, MI3,000 participantsMayo Clinic

View Study Details

NCT07226843Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously t...

Rochester, MI460 participantsEli Lilly and Company

View Study Details

NCT06090539Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrad...

Rochester, MI460 participantsBristol-Myers Squibb

View Study Details

NCT05091424Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic...

Rochester, MI332 participantsHoffmann-La Roche

View Study Details

NCT05700149Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

International retrospective observational cohort study aimed to describe a molecular classification for NMZL....

Rochester, MI300 participantsInternational Extranodal Lymphoma Study Group (IELSG)

View Study Details

NCT06526793Recruiting

AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lympho...

Rochester, MI270 participantsAstraZeneca

View Study Details

NCT04390737Recruiting

Evaluate the Safety and Clinical Activity of HH2853

This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a ...

Rochester, MI254 participantsHaihe Biopharma Co., Ltd.

View Study Details

NCT07058064Recruiting

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and relate...

Rochester, MI250 participantsMayo Clinic

View Study Details

NCT04884035Recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1)...

Rochester, MI224 participantsCelgene

View Study Details

NCT07101328Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the ...

Rochester, MI215 participantsEli Lilly and Company

View Study Details

NCT06542250Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Ma...

Rochester, MI174 participantsAstraZeneca

View Study Details

NCT03328078Recruiting

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult p...

Rochester, MI152 participantsCuris, Inc.

View Study Details

NCT07104032Recruiting

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractor...

Rochester, MI132 participantsOno Pharmaceutical Co., Ltd.

View Study Details

NCT06238648Recruiting

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chi...

Rochester, MI120 participantsAcademic and Community Cancer Research United

View Study Details

NCT06854653Recruiting

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/r...

Rochester, MI115 participantsPrescient Therapeutics, Ltd.

View Study Details

NCT06386315Recruiting

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Ra...

Rochester, MI112 participantsMayo Clinic

View Study Details

NCT05783609Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other trea...

Rochester, MI100 participantsReid Merryman, MD

View Study Details

NCT06098430Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal sy...

Rochester, MI100 participantsSt. Jude Children's Research Hospital

View Study Details

NCT05910801Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that ha...

Rochester, MI100 participantsAcademic and Community Cancer Research United

View Study Details

NCT03017820Recruiting

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients w...

Rochester, MI99 participantsMayo Clinic

View Study Details

NCT07123454Recruiting

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Ref...

Rochester, MI91 participantsAstraZeneca

View Study Details

NCT06634589Recruiting

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed...

Rochester, MI80 participantsBeiGene

View Study Details

NCT03418038Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clon...

Rochester, MI80 participantsMayo Clinic

View Study Details

NCT04669171Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide an...

Rochester, MI80 participantsEnterome

View Study Details

NCT05876923Recruiting

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) an...

Rochester, MI70 participantsMayo Clinic

View Study Details

NCT05294367Recruiting

Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma

This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important...

Rochester, MI60 participantsMayo Clinic

View Study Details

NCT06854003Recruiting

BRAZAN Trial in Frontline MCL

This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubr...

Rochester, MI60 participantsChristine Ryan

View Study Details

NCT06834373Recruiting

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymp...

Rochester, MI41 participantsMayo Clinic

View Study Details

NCT03758989Recruiting

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during trea...

Rochester, MI40 participantsUniversity of Rochester

View Study Details

NCT06828991Recruiting

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Identifying which patients might benefit from...

Rochester, MI40 participantsDanielle Wallace

View Study Details

NCT04892277Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

This phase I trial studies the effects of CD-19 directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of patients with B cell malignancies that have come back (recurrent) or have n...

Rochester, MI25 participantsMayo Clinic

View Study Details

NCT06508463Recruiting

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-...

Rochester, MI21 participantsMayo Clinic

View Study Details

About Lymphoma Clinical Trials in Rochester

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 32 lymphoma clinical trials recruiting participants in Rochester, MI. These studies are seeking a combined 7,657 participants. Research is being sponsored by Mayo Clinic, Eli Lilly and Company, Bristol-Myers Squibb and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Rochester — FAQ

Are there lymphoma clinical trials in Rochester?

Yes, there are 32 lymphoma clinical trials currently recruiting in Rochester, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rochester?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you about next steps.

Are clinical trials in Rochester free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rochester studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 32 active trials in Rochester are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 13, 2026 from ClinicalTrials.gov